论文部分内容阅读
[目的]探讨过继免疫高强度聚焦超声(HIFU)治疗后活化的杀伤性T淋巴细胞(CTL)引起的荷瘤鼠肿瘤免疫功能变化。[方法]C57BL/6J近交系荷瘤鼠在H22肝癌移植后7d分别接受HIFU治疗和HIFU假照治疗,治疗后14d分离两组荷瘤鼠和正常小鼠外周血CTL。选30只H22荷瘤鼠随机分为治疗组、假照组和对照组,分别尾静脉注射之前分离的3组CTL。于过继免疫治疗后2周测定各组小鼠外周血T淋巴细胞亚群的变化,采用MTT法测定脾淋巴细胞的体外杀伤活性,ELISA法检测脾淋巴细胞与肿瘤细胞共培养24h后上清液IFN-γ、TNF-α含量。[结果]CTL过继免疫治疗后2周,与假照组和对照组比较,治疗组小鼠肿瘤体积较小,外周血CD4+水平明显增加,CD8+水平明显降低,CD4+/CD8+的比值明显升高,脾脏淋巴细胞对H22肿瘤细胞毒活性明显增加,与H22肿瘤细胞共培养上清液INF-γ和TNF-α浓度明显增加,差异有显著统计学意义。[结论]HIFU活化的CTL过继免疫治疗H22移植性肝癌,宿主细胞免疫功能增强,同时机体产生抗肿瘤的免疫作用。
[Objective] To investigate the changes of tumor immune function in tumor-bearing mice induced by activated killer T lymphocytes (CTL) after adoptive immunofluorescence high-intensity focused ultrasound (HIFU). [Methods] The C57BL / 6J inbred mice bearing HIFU and HIFU sham were treated with HIFU and HIFU respectively on the 7th day after transplantation of H22 hepatoma. The CTL of the two groups were separated 14 days after the treatment. Thirty H22 tumor-bearing mice were randomly divided into treatment group, sham group and control group. Three groups of CTLs were isolated before tail vein injection. The changes of T lymphocyte subsets in peripheral blood of mice in each group were measured 2 weeks after adoptive immunotherapy. The cytotoxic activity of splenic lymphocytes in vitro was determined by MTT assay. The supernatants of spleen lymphocytes and tumor cells co-cultured with tumor cells IFN-γ, TNF-α content. [Results] Compared with the sham control group and the control group, the tumor volume of mice in treatment group was small, the level of CD4 + in peripheral blood was significantly increased, the level of CD8 + was significantly decreased and the ratio of CD4 + / CD8 + was significantly increased in 2 weeks after adoptive immunotherapy. Splenic lymphocytes on H22 tumor cytotoxicity was significantly increased, and H22 tumor cells co-cultured supernatant INF-γand TNF-αconcentration increased significantly, the difference was statistically significant. [Conclusion] HIFU-activated CTL adoptive immunotherapy can enhance the immune function of host H22 transplanted hepatocellular carcinoma. At the same time, the body produces antitumor immunity.